Eli Lilly Strengthens GLP-1 Leadership Claim – Foundayo Surpasses Oral Semaglutide!
Reading Time: 3 minutes
Eli Lilly is driving its growth through global dominance in the incretin drug market with Mounjaro and Zepbound. Phase 3 data for the new oral formulation Foundayo demonstrate a clear superiority over Novo Nordisk's oral semaglutide in blood sugar control and weight loss. With billion-dollar acquisitions, the business is being diversified beyond metabolic therapies. Eli Lilly (LLY) is engaged in the research, development, and marketing of innovative medications in core areas such as cardiometabolism, oncology, immunology, and neuroscience....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
